Bioactive peptides and proteins as alternative antiplatelet drugs

Rengasamy, Kannan R.R.; Khan, Haroon; Ahmad, Imad; Lobine, Devina; Mahomoodally, Fawzi M.; Suroowan, Shanoo; Hassan, Sherif T. S.; Xu, Suowen; Patel, Seema; Daglia, Maria; Nabavi, Seyed Mohammad; Pandian, Shunmugiah Karutha

doi:10.1002/med.21579

Cited by 24 publications

(12 citation statements)

References 98 publications

(247 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Thus, platelets play an essential role in physiological hemostasis process, and abnormal platelet aggregation is the pathological basis of thrombosis. Platelet aggregation is caused by the rupture of atherosclerotic plaques or endothelial injury and may lead to acute thrombotic occlusive ischemic events when the blood supply to tissues is insufficient or is interrupted by athrombus, 2 which is the underlying mechanism for stroke and myocardial infarction as well as the leading cause of morbidity and mortality worldwide. 3,4 Antiplatelet drugs are the main agents used to prevent and treat acute thrombotic occlusive ischemic events.…”

Section: Introductionmentioning

confidence: 99%

The Synergistic Effect of Ginkgo biloba Extract 50 and Aspirin Against Platelet Aggregation

Huo

et al. 2021

DDDT

View full text Add to dashboard Cite

We aimed to investigate potential synergistic antiplatelet effects of Ginkgo biloba extract (GBE50) in combination with aspirin using in vitro models. Methods: Arachidonic acid (AA), platelet activating factor (PAF), adenosine 5ʹ-diphosphate (ADP) and collagen were used as inducers. The antiplatelet effects of GBE50, aspirin and 1:1 combination of GBE50 and aspirin were detected by microplate method using rabbit platelets. Synergy finder 2.0 was used to analyze the synergistic antiplatelet effect. The compounds in GBE50 were identified by UPLC-Q/TOF-MS analysis and the candidate compounds were screened by TCMSP database. The targets of candidate compounds and aspirin were obtained in TCMSP, CCGs, Swiss target prediction database and drugbank. Targets involving platelet aggregation were obtained from GenCLiP database. Compound-target network was constructed and GO and KEGG enrichment analyses were performed to identify the critical biological processes and signaling pathways. The levels of thromboxane B2 (TXB2), cyclic adenosine monophosphate (cAMP) and PAF receptor (PAFR) were detected by ELISA to determine the effects of GBE50, aspirin and their combination on these pathways. Results: GBE50 combined with aspirin inhibited platelet aggregation more effectively. The combination displayed synergistic antiplatelet effects in AA-induced platelet aggregation, and additive antiplatelet effects occurred in PAF, ADP and collagen induced platelet aggregation. Seven compounds were identified as candidate compounds in GBE50. Enrichment analyses revealed that GBE50 could interfere with platelet aggregation via cAMP pathway, AA metabolism and calcium signaling pathway, and aspirin could regulate platelet aggregation through AA metabolism and platelet activation. ELISA experiments showed that GBE50 combined with aspirin could increase cAMP levels in resting platelets, and decreased the levels of TXB2 and PAFR. Conclusion:Our study indicated that GBE50 combined with aspirin could enhance the antiplatelet effects. They exerted both synergistic and additive effects in restraining platelet aggregation. The study highlighted the potential application of GBE50 as a supplementary therapy to treat thrombosis-related diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

The Synergistic Effect of Ginkgo biloba Extract 50 and Aspirin Against Platelet Aggregation

Huo

et al. 2021

DDDT

View full text Add to dashboard Cite

show abstract

“…Bioactive peptides from foods such as dairy products, seafood, seaweeds, nuts, cereals, and other natural sources possess antithrombotic properties that may be useful as antiplatelet agents as they seem to interact with multiple platelet activation pathways. These include inhibition of cyclooxygenase-1 (COX-1), inhibition of type-III collagen-induced aggregation, binding to glycoprotein IIb/IIIa, interacting with fibrinogen and its receptor, and affecting thrombin (73,74).…”

Section: Foods and Nutrients With Antithrombotic Propertiesmentioning

confidence: 99%

Thrombosis and COVID-19: The Potential Role of Nutrition

2020

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease (COVID-19), is a contagion that has rapidly spread around the globe. COVID-19 has caused significant loss of life and disrupted global society at a level never before encountered. While the disease was predominantly characterized by respiratory symptoms initially, it became clear that other systems including the cardiovascular and neurological systems were also involved. Several thrombotic complications were reported including venous thrombosis, vasculitis, cardiomyopathy, and stroke. Thrombosis and inflammation are implicated in various non-communicable diseases (NCDs). This is of significant concern as people with pre-existing conditions such as cardiovascular disorders, renal disorders, obesity, metabolic syndrome, and diabetes are at greater risk of severe COVID-19 infection. Consequently, the research surrounding the use of anticoagulants, antiplatelet, and antithrombotic strategies for prophylaxis and treatment of COVID-19 is of critical importance. The adoption of a healthy diet, physical exercise, and lifestyle choices can reduce the risk factors associated with NCDs and the thrombo-inflammatory complications. In this review, these thrombotic complications and potential foods, nutraceuticals, and the antithrombotic constituents within that may prevent the onset of severe thrombotic complications as a result of infection are discussed. While nutrition is not a panacea to tackle COVID-19, it is apparent that a patient's nutritional status may affect patient outcomes. Further intensive research is warranted to reduce to incidence of thrombotic complications.

show abstract

“…have drawn special attention due to their special biocompatibility and outstanding health benefits. [16][17][18][19][20] Early epidemiological studies have shown that long-term tea consumption can play a preventive and therapeutic role in cardiovascular diseases. 21 Wang et al grouped the population according to the consumption of tea and found that the incidence of coronary heart disease in the group with the highest green tea consumption was significantly lower than that with the lowest tea consumption.…”

Section: Introductionmentioning

confidence: 99%